Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation
IND.227 - A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma - was centrally activated today, October 7, 2017.

The primary objective of this study is to evaluate whether pembrolizumab, alone or given to patients receiving standard chemotherapy, improves progression-free survival in malignant pleural mesothelioma (MPM) compared to standard chemotherapy.

Secondary objectives include to:
  • Evaluate the tolerability of pembrolizumab, alone or given to patients receiving standard chemotherapy;
  • Assess antitumour activity of pembrolizumab, alone or given to patients receiving standard chemotherapy, including response rate and overall survival; and,
  • Evaluate quality of life effects of pembrolizumab, alone or given to patients receiving standard chemotherapy.
Qualified centres interested in participating should contact Joana Sederias, Study Coordinator, at jsederias@ctg.queensu.ca.